Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

17/86 subjects), with no

differences among the active drug group and the placebo group

* Plasma levels of larazotide acetate were below the limits of

quantification (0.5 ng/ml) in all groups at days 0, 7 and 14

"Although the primary study outcome was not statistically significant, a great deal was learned about the potential effects of larazotide acetate and the secondary outcome data is very positive. Further, important new information was gained about the best way to run a celiac disease clinical trial. This trial marks the beginning of a new era in celiac therapeutics where modalities beyond diet alone have the ability to improve the lives of our patients," stated Daniel Leffler, MD a gastroenterologist from Beth Israel Deaconess Medical Center.

"We are very encouraged by the clear trend in the reduction of intestinal permeability and the signs and symptoms of gluten exposure in patients with celiac disease. We have applied the knowledge gained in this Phase IIa clinical trial to a larger Phase IIb gluten challenge study which is currently ongoing. In addition, we have recently initiated a clinical trial in 106 active celiac disease patients. Alba is committed to developing and studying new treatment options for patients with celiac disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tole
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, announced today ... Hercules Technology Growth Capital, Inc. (NYSE: HTGC ... advance under the Loan and Security Agreement that Alimera,s ... Alimera Sciences Limited, entered into with Hercules in April ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... CAMBRIDGE, Mass., Dec. 22, 2011  Inspiration Biopharmaceuticals, Inc. ... the development and commercialization of new treatment options ... Company has expanded its leadership team with four ... Inspiration as Chief Medical Officer; Daniel Regan as ...
... Dec. 22, 2011  PTC Therapeutics, Inc. (PTC) today ... Drug Discovery (SDD) Award from the Wellcome Trust ... target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative ... Award from the Wellcome Trust to support its ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 2Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 3Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 4Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 5PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... say finding could be key to new disease-fighting therapies ... on mice suggests inhibiting a protein that allows certain ... to cancer-fighting treatments. , A study by Pierre Sonveaux ... found that tumor cells use different fuel sources depending ...
... A team of researchers at Duke University Medical Center and ... acid is an important energy source for tumor cells. In ... most hard-to-kill, dangerous tumor cells by preventing them from delivering ... than 50 years that low-oxygen, or hypoxic, cells cause resistance ...
... MORRISTOWN, N.J., Nov. 20 /PRNewswire/ Bayer HealthCare,has donated hundreds ... New Jersey,(CFBNJ) in response to an urgent call from ... supplies at the state,s food banks. , ... , Mary Lou Panzano, director, US Internal ...
... cancer patients who underwent a mastectomy who undergo ... reconstruction provides fewer long-term complications and better cosmetic ... to a study in the November issue of ... the official journal of the American Society for ...
... Alzheimer,s relatives at risk for hospital visits of their own ... providing care for a loved one with Alzheimer,s results in ... room or hospital visit every six months, says an Indiana ... care of an Alzheimer,s patient is difficult, but the Indiana ...
... Centre Finalizes Construction Plan and Begins Marketing; John Strong, ... Inc., to Lead Sales and Marketing Efforts , ... The world,s first permanent international healthcare marketplace and ... the key players driving the project said today, as ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2Health News:Type of breast reconstruction impacts radiation therapy outcomes 2Health News:When the Caregiver Becomes the Patient 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... PulmoAide Compact Compressor provides effective therapy at an ... therapy at home or on the go and ... the same reliable operation you have come to ... Compressor is the perfect solution for those patients ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Medicine Products: